Atheon Bio is revolutionizing immune-oncology by pushing the limits of what was once thought impossible, bringing the treatments to patients worldwide. We introduce an innovative therapeutic strategy to address the challenge faced by solid cancer patients who do not benefit from existing immune-oncology treatments, particularly those resistant to checkpoint inhibitors. Our leading pipeline, ATN001, is a groundbreaking first-in-class antibody that inhibits a novel target of the tumor microenvironment (TME), recognized as a key player in the angiogenesis and immunosuppression seen in solid tumors. ATN001 stands out with its dual action, simultaneously regulating anti-angiogenesis and immune activation to reprogram the TME. This positions ATN001 as a novel treatment option for patients with solid cancers who have seen limited or no success with immune checkpoint inhibitors, potentially setting a new standard in how solid tumors are managed.